CEO Vas Narasimhan said the company has built up its U.S. inventories to help mitigate the impact of tariffs this year.

Vas Narasimhan, Novartis CEO, joins 'Money Movers' to discuss tariffs on pharmaceuticals, second quarter earnings and outlook ...

W hen Donald Trump’s tariffs are mentioned, you might recall his “Liberation Day” duties on uninhabited islands, his on-again ...

A generous grace period would give drugmakers time to sidestep most of the pain of looming duties.

Drugmaker Swedish Orphan Biovitrum AB’s Chief Executive Officer Guido Oelkers said he doesn’t think tariff threats on the ...

President Trump is readying plans for industry-specific tariffs to kick in alongside his country-by-country duties in two ...

Finally, don't discount legal challenges to the president's tariffs. An argument could be made that pharmaceutical products ...

A 200% tariff rate — even with a delay — will have a detrimental effect on drug prices and profit margins, analysts warn.

After Trump's announcement, Commerce Secretary Howard Lutnick told CNBC that details on pharmaceutical tariffs would come at ...

President Trump said he was likely to impose tariffs on pharmaceuticals as soon as the end of the month, starting with a "low ...

President Donald Trump threatened tariffs of up to 200% on pharmaceuticals imported into the United States — but added that the levies wouldn’t likely be imposed for a year or more.

The US is Australia’s biggest export market for pharmaceuticals. If the tariffs go ahead, manufacturing could suffer.